There is already evidence that mTOR and its upstream activator, IGF1R, are the direct targets of miR-99a in lung cancer, esophageal squamous cell carcinoma, acute lymphoblastic leukaemia as well as HCC [21, 34–36]. This evidence concerns the gene MTOR and hepatocellular carcinoma.